Tracer library / [68Ga]Ga-DOTA-D-Phe-Tyr3-octreotide

[68Ga]Ga-DOTA-D-Phe-Tyr3-octreotide

Also written as DOTA-D-Phe-Tyr3-octreotide; Ga-68 DOTA-D-Phe-Tyr3-octreotide; Ga-68-DOTA-D-Phe-Tyr3-octreotide

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Neuroendocrine neoplasms

What it is

Compound class: radiolabeled somatostatin analog
Target / mechanism: Somatostatin receptor (SSTR) PMID 42606001
Clinical application: Neuroendocrine tumors/neoplasms PMID 42526976
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [68Ga]Ga-DOTA-D-Phe-Tyr3-octreotide, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph: not verified No Ph. Eur. check is recorded for this entry.
USP monograph: not verified No USP check is recorded for this entry.

AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activityMetal impuritiesGe-68 breakthrough

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator production assumed (no synthesis data found) -> Ge-68 breakthrough (preliminary); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-DOTA-D-Phe-Tyr3-octreotide.

Get in touch

Notes

Added from reverse module search (stage 6); 2 article(s) with Ga-68. | Stage 30 (2026-09-18): Stage was 'approved/clinical use'; normalised to 'Clinical research', original wording kept here.